BridgeBio Pharma, Inc.BBIOEarnings & Financial Report
Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...
BBIO Q4 FY2025 Key Financial Metrics
Revenue
$154.2M
Gross Profit
$146.1M
Operating Profit
$-139.6M
Net Profit
$-194.6M
Gross Margin
94.7%
Operating Margin
-90.5%
Net Margin
-126.2%
YoY Growth
2521.2%
EPS
$-1.00
BridgeBio Pharma, Inc. Q4 FY2025 Financial Summary
BridgeBio Pharma, Inc. reported revenue of $154.2M (up 2521.2% YoY) for Q4 FY2025, with a net profit of $-194.6M (up 27.2% YoY) (-126.2% margin). Cost of goods sold was $8.1M, operating expenses totaled $285.6M.
Key Financial Metrics
| Total Revenue | $154.2M |
|---|---|
| Net Profit | $-194.6M |
| Gross Margin | 94.7% |
| Operating Margin | -90.5% |
| Report Period | Q4 FY2025 |
BridgeBio Pharma, Inc. Annual Revenue by Year
BridgeBio Pharma, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $502.1M).
BridgeBio Pharma, Inc. Quarterly Revenue & Net Profit History
BridgeBio Pharma, Inc. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $154.2M | +2521.2% | $-194.6M | -126.2% |
| Q3 FY2025 | $120.7M | +4318.0% | $-184.9M | -153.2% |
| Q2 FY2025 | $110.6M | +4999.9% | $-183.8M | -166.2% |
| Q1 FY2025 | $116.6M | -44.8% | $-169.6M | -145.4% |
| Q1 FY2024 | $211.1M | +11461.9% | $-36.2M | -17.1% |
| Q2 FY2022 | $73.7M | +36.5% | $-2.6M | -3.5% |
Income Statement
| Q2 2022 | Q1 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $73.7M | $211.1M | $116.6M | $110.6M | $120.7M | $154.2M |
| YoY Growth | 36.5% | 11461.9% | -44.8% | 4999.9% | 4318.0% | 2521.2% |
Balance Sheet
| Q2 2022 | Q1 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Assets | $862.2M | $849.3M | $881.6M | $1.08B | $998.3M | $936.0M |
| Liabilities | $1.88B | $1.89B | $2.52B | $2.86B | $2.92B | $3.01B |
| Equity | $-1.03B | $-1.05B | $-1.65B | $-1.79B | $-1.93B | $-2.09B |
Cash Flow
| Q2 2022 | Q1 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $-30.5M | $-219.5M | $-199.2M | $-80.7M | $-109.6M | $-56.4M |